Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved isatuximab-irfc (Sarclisa, Sanofi-Aventis) with bortezomib, lenalidomide and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for an autologous stem cell transplant (ASCT).
Efficacy was evaluated in IMROZ (ClinicalTrials.gov. Identifier: NCT03319667), an open-label, randomized, active-controlled, phase 3 trial in patients with newly diagnosed